A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Status:
Recruiting
Trial end date:
2022-06-07
Target enrollment:
Participant gender:
Summary
The main objective of the study is to evaluate the pharmacokinetics of brensocatib in
participants with cystic fibrosis following once daily oral administration of study drug and
to evaluate the safety of brensocatib compared to placebo in participants with cystic
fibrosis (CF) over the 4-week treatment period.